Tag: Starpharma

Australian biopharmaceutical company Starpharma has secured a sales and distribution agreement for its VivaGel BV product in the Middle East and North Africa (MENA) region. 

Biopharmaceutical company Starpharma Holdings has ventured into a partnership with the University of Queensland’s (UQ) Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR Hub) to advance research and development on the ASX company’s targeted DEP radiotheranostic products. 

Australian biotech firm Starpharma announced that its VIRALEZE antiviral nasal spray has been successfully registered for sale in Europe, including in the UK. VIRALEZE is...

ASX-listed pharmaceutical company Starpharma has announced that it has undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and...

Australian company Starpharma has signed a milestone deal with global pharmaceutical giant AstraZeneca to further develop a Dendrimer Enhanced Product (DEP) version of one...

Melbourne-based biotechnology company Starpharma Holdings has sold its agrochemical business to Agrium for A$35 million. The Starpharma agrochemical business, which is focused on development of...

Starpharma Holdings Limited — world leading developer of dendrimer products for pharmaceutical, life-science and other applications — has announced that its VivaGel® condom has received...